Kailera Therapeutics Quarterly Cash Flow Statement
NASDAQ: KLRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.61+1.61 (+16.10%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kailera Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Kailera Therapeutics generated -$77.5 million of operating cash flow. That left free cash flow of -$77.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Kailera Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Net Income | -111.31M | -78.86M | -28.95M | -17.98M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 101.00K | 101.00K | 62.00K | 63.00K |
| Stock-Based Compensation | 8.34M | 3.94M | 1.63M | 1.52M |
| Change in Working Capital | 11.05M | -453.00K | -4.34M | -2.03M |
| Operating Cash Flow | -77.53M | -68.31M | -26.23M | -18.20M |
| Investing Cash Flow | -571.02M | 22.85M | -74.17M | -54.44M |
| Financing Cash Flow | 667.03M | -2.98M | 100.00M | 0 |
| Net Change in Cash | 18.48M | -48.44M | -403.00K | -72.64M |
| Free Cash Flow | -77.53M | -68.31M | -26.23M | -18.20M |
This table shows 4 quarterly periods of Kailera Therapeutics's cash flow statement, from Q2 2026 back to Q? 2025, across 9 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow KLRA's reporting calendar. What is a cash flow statement?